Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the (1) benefits and (2) risks of using wearable technology and AI-driven monitoring systems to track vital signs in patients who are prescribed semaglutide; and whether those systems could be used to automatically alert healthcare providers or patients in the event of adverse reactions.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Institute for Health and Care Excellence has published early value assessment guidance on digital technologies for delivering multidisciplinary weight management services. This includes recommendations on which technologies can be used in the National Health Service to prescribe and monitor obesity medicines and deliver multidisciplinary weight-management services in adults.

The Department has not commissioned, and has no current plans to commission, research or an assessment into the use of artificial intelligence or wearable technology for people using obesity medicines. However, we recognise the potential of artificial intelligence, wearable technologies, and monitoring systems to support people’s health and care, including through the monitoring of vital signs.

Whilst we have not made a specific assessment of their use in patients prescribed semaglutide, we are actively exploring where these technologies can be safely, effectively, and appropriately used in the health and care system. Ensuring the safe integration of wearable technologies and artificial intelligence into clinical pathways requires careful consideration and collaboration with clinicians, patients, and technology developers.

Question to the Department of Health and Social Care:

To ask His Majesty's Government whether they have commissioned, or plan to commission, studies into the use of artificial intelligence to monitor individuals who purchase semaglutide for weight loss, particularly in regard to patient follow-up and supervision.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Institute for Health and Care Excellence has published early value assessment guidance on digital technologies for delivering multidisciplinary weight management services. This includes recommendations on which technologies can be used in the National Health Service to prescribe and monitor obesity medicines and deliver multidisciplinary weight-management services in adults.

The Department has not commissioned, and has no current plans to commission, research or an assessment into the use of artificial intelligence or wearable technology for people using obesity medicines. However, we recognise the potential of artificial intelligence, wearable technologies, and monitoring systems to support people’s health and care, including through the monitoring of vital signs.

Whilst we have not made a specific assessment of their use in patients prescribed semaglutide, we are actively exploring where these technologies can be safely, effectively, and appropriately used in the health and care system. Ensuring the safe integration of wearable technologies and artificial intelligence into clinical pathways requires careful consideration and collaboration with clinicians, patients, and technology developers.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the use of AI-integrated health monitoring tools to manage unsupervised use of medications such as semaglutide.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Currently, no assessment has been made on the use of artificial intelligence (AI) to monitor the unsupervised use of these medications. However, we recognise the potential of AI and monitoring systems to support people’s health and care, including through the monitoring of vital signs. The United Kingdom has a world-leading regulatory system which ensures that medical technologies on the market are safe for use, including AI technologies. Should the National Health Service begin to assess AI-integrated health monitoring tools, they will be held to the same regulatory standards as other tools used by the NHS.

Medications such as semaglutide are prescription only medicines and should not be used unsupervised. It is illegal to obtain a prescription medicine without a prescription.

Question to the Department for Business and Trade:

To ask His Majesty's Government what insights or lessons from the UK pavilion at Expo 2020 in Dubai have informed the planning and design of the UK pavilion at Expo 2025 in Osaka, which opened on 13 April.

Answered by Baroness Gustafsson - Minister of State (Department for Business and Trade)

DBT have taken lessons learned from previous Expos and other major events (including Commonwealth Games and Investment Summits) to inform the planning and design of the UK Pavilion at Expo Osaka.

Question to the Department for Science, Innovation & Technology:

To ask His Majesty's Government what plans they have to develop UK sovereign AI capacity; and on what timeframe.

Answered by Lord Vallance of Balham - Minister of State (Department for Science, Innovation and Technology)

The AI Opportunities Action Plan, launched in January, outlines 50 actions to drive AI development and deployment. The government has committed to taking forward all recommendations, including the establishment of a new, sovereign AI unit with a clear mandate to maximise the UK's stake in frontier AI.

Building sovereign capabilities will enable the UK to harness the economic potential of advanced AI whilst safeguarding our national security, in the context of rapid AI development. The government has already partnered with leading AI companies, such as Anthropic, to explore AI opportunities in the UK. More details of the sovereign AI programme will be announced in due course.

Question to the Department for Business and Trade:

To ask His Majesty's Government what assessment they have made of the costs and benefits of the UK Pavilion at Expo 2020 Dubai; and whether the findings of that assessment will be made publicly available.

Answered by Baroness Gustafsson - Minister of State (Department for Business and Trade)

DBT conducted an evaluation of the UK presence at Expo 2020 Dubai. This provided accountability and learning to inform continuous improvements. The lessons are directly feeding into planning and delivery of the UK presence at Expo 2025 Osaka.

Question to the Department for Science, Innovation & Technology:

To ask His Majesty's Government which ministers, officials, and external experts attended the meeting held at 10 Downing Street on Wednesday 16 April regarding the establishment of UK sovereign AI capacity; and what criteria were used to select the expert participants.

Answered by Lord Vallance of Balham - Minister of State (Department for Science, Innovation and Technology)

The AI Opportunities Action Plan, launched in January, outlines 50 actions to drive AI development. We are committed to strengthening the UK sector and supporting the emergence of leading UK AI companies. A broad programme of engagement is a critical part of this commitment. The sovereign AI team has engaged with a wide range of stakeholders, including academics, founders, and investors throughout the UK and will continue to do so.

This recent event, focused on building UK capabilities, was part of that ongoing engagement, and participants were invited accordingly.

Ministerial meetings are published according to normal transparency requirements on the GOV.UK website.

Found: LORD FREYBERG THE EARL OF CLANCARTY LORD HENDY 204_ [Withdrawn] LORD DAVIES OF BRIXTON 204A_ After

Found: LORD FREYBERG THE EARL OF CLANCARTY LORD HENDY 204_ [Withdrawn] LORD DAVIES OF BRIXTON 204A_ After

Found: LORD FREYBERG 150A_ [Withdrawn] Employment Rights Bill 38 Schedule 4 BARONESS BARRAN 151_ Schedule

Found: LORD FREYBERG THE EARL OF CLANCARTY LORD HENDY 204_ [Withdrawn] LORD DAVIES OF BRIXTON 204A_ After

Found: LORD FREYBERG THE EARL OF CLANCARTY LORD HENDY 204_ [Withdrawn] LORD DAVIES OF BRIXTON 204A_ After

Found: LORD FREYBERG THE EARL OF CLANCARTY LORD HENDY 204_ After Clause 54, insert the following new Clause

Found: of this Bill on SMEs within six months of the passage of this Act. 115 Employment Rights Bill LORD FREYBERG

Found: MOVED IN COMMITTEE OF THE WHOLE HOUSE [Supplementary to the Marshalled List] After Clause 34 LORD FREYBERG